
ImPact Biotech shows promising Phase 1 and 3 trial results for Padeliporfin VTP in pancreatic and urothelial cancers
ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026...

